Actively Recruiting
Pilot Study Evaluating Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation Treatment
Led by Virginia Commonwealth University · Updated on 2026-01-27
33
Participants Needed
1
Research Sites
67 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the use of topical azelaic acid applied twice daily to evaluate its feasibility in breast cancer patients undergoing radiation therapy. This pilot study focuses on patients who self-identify as Black, Asian, Hispanic/Latin, or ethnically from the Mediterranean or Pacific rim, and who tan easily. The study is conducted during the phase 1 stage, aiming to understand how well patients can use this treatment alongside their radiation schedule and to assess the treatment process.
CONDITIONS
Official Title
Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Self-report as Black, Asian, Hispanic/Latin, or ethnically from the Mediterranean or Pacific rim, or tan easily in the sun
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Patient confirms not pregnant, lactating, or planning pregnancy/fathering during the study
- Histologic confirmation of breast cancer with TNM staging
- Radiation treatment plan includes specific whole breast or chest wall radiation types and doses
- Radiation may include treatment of regional lymph nodes, tumor bed boost, and tissue-equivalent bolus as decided by physician
- Radiation will be photon-based, with possible use of photons and/or electrons if boost given
You will not qualify if you...
- Prior radiotherapy to planned treatment site
- Current inflammatory breast cancer or gross skin involvement at radiation start
- Use of immunotherapy or cytotoxic chemotherapy during radiation (HER2 or endocrine therapy allowed)
- Active rash or dermatitis in treatment area or history of such conditions there
- Active collagen vascular diseases like lupus, scleroderma, or dermatomyositis
- History of organ or bone marrow transplant
- Allergy or hypersensitivity to azelaic acid ingredients
- Use within 28 days before baseline of topical/oral retinoids, certain systemic antibiotics, systemic corticosteroids or immunosuppressants (except some chemotherapy or IV contrast allergy treatments)
- Use within 2 weeks before baseline of topical corticosteroids, antibiotics, or skin rash medications on treated breast
- Planned radiation is proton or carbon therapy
- Use of external beam partial breast irradiation, brachytherapy, or intraoperative radiation
- Medical, psychological, or social conditions that may increase risk or limit study adherence
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Actively Recruiting
Research Team
M
Massey IIT Research Operations
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here